Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07390617 · ClinicalTrials.gov registry record
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
A clinical trial of Urothelial Carcinoma and Metastatic Urothelial Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 7
- Study locations
NCT07390617 is a study of Urothelial Carcinoma and Metastatic Urothelial Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (79% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT07390617, a study of Urothelial Carcinoma and Metastatic Urothelial Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)
Conditions Studied
Interventions
- OTHER Non-therapeutic Nerve Conduction Studies
- OTHER Non-therapeutic assessment of patient-reported neuropathy
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2028-01-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07390617
The ClinicalTrials.gov registry entry for NCT07390617 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (79% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Non-therapeutic Nerve Conduction Studies is the first listed.
NCT07390617 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07390617 about?
NCT07390617 is a clinical study titled "A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma". The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)
What is the current status of trial NCT07390617?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2026-01-20. Estimated completion is 2028-01-20.
What conditions does trial NCT07390617 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Neuropathy.
What interventions are being tested in trial NCT07390617?
The interventions under investigation include: Non-therapeutic Nerve Conduction Studies (OTHER), Non-therapeutic assessment of patient-reported neuropathy (OTHER).
Who is sponsoring clinical trial NCT07390617?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07390617 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.